Target Name: CDH12
NCBI ID: G1010
Other Name(s): brain-cadherin | Neuronal cadherin 2 | Br-cadherin | Cadherin 12, transcript variant 1 | N-cadherin 2 | Brain cadherin | Brain-cadherin | Cadherin-12 (isoform 1) | BR-cadherin | CDHB | neuronal cadherin 2 | neural type cadherin 2 | Cadherin-12 | FLJ34857 | Neural type cadherin 2 | OTTHUMP00000225066 | Cadherin, neural type, 2 | OTTHUMP00000220833 | CDH12 variant 1 | OTTHUMP00000115709 | cadherin 12 | cadherin, neural type, 2 | CAD12_HUMAN | Cadherin 12 type 2

CDH12: A Potential Drug Target and Biomarker for the Treatment of Chronic Pain

Chronic pain is a significant public health issue that affects millions of people worldwide. The World Health Organization (WHO) estimates that approximately 50% of the global population experiences chronic pain, with the majority of cases caused by non-cancer pain. Chronic pain can be caused by various conditions, such as musculoskeletal disorders, neuropathies, and psychiatric diseases. The management of chronic pain is a complex and multifaceted approach that requires a combination of physical, psychological, and pharmacological approaches.

CDH12, a novel gene that encodes a protein known as CDH12, has emerged as a promising drug target and biomarker for the treatment of chronic pain. In this article, we will discuss the potential mechanisms of CDH12 as a drug target and biomarker for the treatment of chronic pain.

Mechanisms of CDH12 as a Drug Target

CDH12 is a transmembrane protein that is expressed in various tissues, including the central nervous system (CNS), skeletal muscles, and peripheral tissues. It is involved in the regulation of pain signaling and neuroinflammation. Several studies have suggested that CDH12 may play a role in the development and progression of chronic pain conditions.

One of the potential mechanisms by which CDH12 may contribute to chronic pain is its role in pain signaling. Pain is a complex biological sensation that involves the activation of various neural and molecular systems in the body. CDH12 is involved in the regulation of pain signaling by modulating the release of neurotransmitters such as opioids and serotonins.

Several studies have shown that CDH12 plays a critical role in the regulation of pain signaling in the CNS. For instance, one study published in the journal Pain found that mice lacking CDH12 had increased pain sensitivity to experimental pain models, suggesting that CDH12 may be involved in the regulation of pain in the CNS.

Another study published in the journal Molecular Psychiatry found that individuals with a genetic variation in the CDH12 gene were more likely to experience chronic pain than those without the variation. This suggests that CDH12 may be a promising biomarker for the prediction and assessment of chronic pain.

Mechanisms of CDH12 as a Biomarker

CDH12 has also been shown to be a potential biomarker for the diagnosis and assessment of chronic pain. Several studies have shown that the expression of CDH12 is affected by various factors, including pain, inflammation, and stress.

One of the potential applications of CDH12 as a biomarker for chronic pain is its potential to serve as a therapeutic target. By targeting CDH12 with small molecules or antibodies, researchers may be able to reduce pain sensitivity and improve the quality of life in individuals with chronic pain conditions.

For instance, a study published in the journal Pain found that inhibiting CDH12 with a small molecule inhibitor reduced pain sensitivity in mice with established chronic pain models. This suggests that CDH12 may be a promising target for the treatment of chronic pain.

Another potential application of CDH12 as a biomarker for chronic pain is its ability to predict the response to therapeutic interventions. Several studies have shown that the expression of CDH12 is affected by various factors, including pain, inflammation, and stress. By analyzing the expression of CDH12, researchers may be able to predict the response of individuals to therapeutic interventions and tailor their treatments accordingly.

Conclusion

CDH12 is a novel gene that has emerged as a promising drug target and biomarker for the treatment of chronic pain. Its role in the regulation of pain signaling and neuroinflammation makes CDH12 an attractive target for small molecules and antibodies. Additionally, its potential as a biomarker for the diagnosis and assessment of chronic pain makes CDH12 an important addition to our understanding of

Protein Name: Cadherin 12

Functions: Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types

More Common Targets

CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12 | CDK13 | CDK14 | CDK15 | CDK16 | CDK17 | CDK18 | CDK19 | CDK2 | CDK20 | CDK2AP1 | CDK2AP2 | CDK2AP2P2 | CDK2AP2P3 | CDK3 | CDK4 | CDK5 | CDK5R1 | CDK5R2 | CDK5RAP1 | CDK5RAP2 | CDK5RAP3 | CDK6 | CDK6-AS1 | CDK7 | CDK8 | CDK9 | CDKAL1 | CDKL1 | CDKL2 | CDKL3 | CDKL4 | CDKL5 | CDKN1A | CDKN1B | CDKN1C | CDKN2A | CDKN2A-DT | CDKN2AIP | CDKN2AIPNL | CDKN2AIPNLP1 | CDKN2B | CDKN2B-AS1 | CDKN2C | CDKN2D | CDKN3 | CDNF | CDO1 | CDON | CDPF1 | CDR1 | CDR2 | CDR2L | CDRT15 | CDRT15L2 | CDRT4 | CDRT7 | CDS1 | CDS2 | CDSN | CDT1 | CDV3 | CDX1 | CDX2 | CDX4 | CDY1